title: Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer.
abstract: 5-Fluorouracil and leucovorin plus oxaliplatin (FOLFOX) or capecitabine plus oxaliplatin (XELOX) is a standard adjuvant treatment for patients with stage III colon cancer (CC). Capecitabine is an oral fluoropyrimidine, and administration of oxaliplatin does not necessarily require the insertion of a central venous access device (CVAD). We evaluated the feasibility of XELOX without a CVAD as adjuvant treatment in patients with stage III CC.
  
  
  
  We retrospectively studied prospectively collected data from patients with stage III CC treated with XELOX in the International Duration Evaluation of Adjuvant Chemotherapy French trial. Patients were divided into 2 groups: those with a CVAD and those with peripheral venous access (PVA), including patients who had and had not had a CVAD at the first cycle of chemotherapy. Chemotherapy without a CVAD was considered feasible if the patient received all cycles of adjuvant therapy without it.
  
  
  
  A total of 203 patients were included: 86 (43%) in the PVA group and 116 (57%) in the CVAD group. Of the 85 patients in the PVA group (1 patient was not treated), 69 (81.2%) did not require the insertion of a CVAD. However, 16 (18.8%) required CVAD insertion owing to systematic delay of the initially planned CVAD before the second cycle of chemotherapy in 7, complications related to PVA usage in 5, a switch to the modified FOLFOX6 regimen in 2, and other reasons in 2. The oxaliplatin dose was similar in both groups regardless of the chemotherapy duration. XELOX without a CVAD was feasible for 81.2% of the patients for whom a CVAD had not been planned before chemotherapy and for 88.4% of patients for whom chemotherapy was planned without the use of a CVAD.
  
  
  
  XELOX chemotherapy without a CVAD is a feasible approach for treating patients with stage III CC in the adjuvant setting.
authors.affiliation: Department of Gastroenterology and Digestive Oncology, Hôpital Européen Georges Pompidou, Paris, France; Multidisciplinary Oncology Research Group (Groupe Coopérateur Multidisciplinaire en Oncologie), Paris, France.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Lapeyre-Prost
authors.affiliation: Multidisciplinary Oncology Research Group (Groupe Coopérateur Multidisciplinaire en Oncologie), Paris, France.
authors.forename: Marine
authors.initials: M
authors.lastname: Hug de Larauze
authors.affiliation: Multidisciplinary Oncology Research Group (Groupe Coopérateur Multidisciplinaire en Oncologie), Paris, France; Department of Medical Oncology, Institut Hospitalier Franco-Britannique, Levallois-Perret, France.
authors.forename: Benoist
authors.initials: B
authors.lastname: Chibaudel
authors.affiliation: Department of Medical Oncology, Hôpital Saint-Antoine, Paris, France.
authors.forename: Marie Line
authors.initials: ML
authors.lastname: Garcia
authors.affiliation: Department of Medical Oncology, Institut de Cancérologie de l'Ouest Paule Papin, Angers, France.
authors.forename: Veronique
authors.initials: V
authors.lastname: Guering-Meyer
authors.affiliation: Department of Gastroenterology and Digestive Oncology, Hôpital Robert Debré, Reims, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Bouché
authors.affiliation: Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.
authors.forename: Eveline
authors.initials: E
authors.lastname: Boucher
authors.affiliation: Department of Medical Oncology, Centre Régional de Lutte Contre le Cancer Val d'Aurelle, Montpellier, France.
authors.forename: Marc
authors.initials: M
authors.lastname: Ychou
authors.affiliation: Department of Medical Oncology, Hôpital Layne, Mont-de-Marsan, France.
authors.forename: Jérôme
authors.initials: J
authors.lastname: Dauba
authors.affiliation: Department of Hepatogastroenterology, Centre Hospitalier Universitaire Carémeau, Nîmes, France.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Obled
authors.affiliation: Department of Medical Oncology, Institut Curie, Hôpital René Huguenin, Saint-Cloud, France; Université Versailles Saint-Quentin-en-Yvelines, Versailles, France.
authors.forename: Astrid
authors.initials: A
authors.lastname: Lièvre
authors.affiliation: Department of Surgical Oncology, Institut Gustave Roussy, Villejuif, France; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
authors.forename: David
authors.initials: D
authors.lastname: Malka
authors.affiliation: Department of Gastroenterology, Centre Hospitalier Départemental de La Roche-sur-Yon Les Oudairies, Roche-sur-Yon, France.
authors.forename: Roger
authors.initials: R
authors.lastname: Faroux
authors.affiliation: Department of Medical Oncology, Hôpital Jean Bernard, Valenciennes, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Bonnet
authors.affiliation: Department of Gastroenterology and Digestive Oncology, Hôpital Européen Georges Pompidou, Paris, France.
authors.forename: Julien
authors.initials: J
authors.lastname: Taieb
authors.affiliation: Multidisciplinary Oncology Research Group (Groupe Coopérateur Multidisciplinaire en Oncologie), Paris, France; Department of Medical Oncology, Hôpital Saint-Antoine, Paris, France; Université Pierre et Marie Curie Paris 6, Paris, France. Electronic address: thierry.andre@aphp.fr.
authors.forename: Thierry
authors.initials: T
authors.lastname: André
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000069287:Capecitabine; D062905:Central Venous Catheters; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018572:Disease-Free Survival; D005240:Feasibility Studies; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010071:Oxaloacetates; D012189:Retrospective Studies
chemical_list: D010071:Oxaloacetates; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil
keywords: Adjuvant chemotherapy; CVAD; Colon cancer; Peripheral venous access; XELOX